GOSS Insider Trading
Gossamer Bio, Inc. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Gossamer Bio, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-20 23:04 | 2025-08-19 | Milligan Sandra | Director | BUY | $1.92 | 26,050 | $50,016 | 58,050 | +81.4% |
| 2024-06-26 01:24 | 2024-06-24 | Aranda Richard | Officer - Chief Medical Officer | SELL | $0.66 | 1,908 | $1,260 | 196,891 | -1.0% |
| 2024-06-25 00:52 | 2024-06-21 | Hasnain Faheem | Director, Officer - President & CEO | BUY | $0.67 | 372,000 | $250,282 | 5,408,073 | +7.4% |
| 2024-06-21 03:21 | 2024-06-18 | Giraudo Bryan | Officer - COO/CFO | BUY | $0.59 | 100,000 | $59,110 | 480,010 | +26.3% |
| 2024-06-21 03:20 | 2024-06-17 | Smith Robert Paul JR | Officer - Chief Commercial Officer | BUY | $0.60 | 25,000 | $15,050 | 25,000 | +100.0% |
| 2024-03-29 01:05 | 2024-03-27 | Giraudo Bryan | Officer - COO/CFO | SELL | $1.16 | 6,430 | $7,431 | 92,737 | -6.5% |
| 2024-03-29 01:16 | 2024-03-27 | Christian Waage | Officer - EVP, Tech Ops and Admin | SELL | $1.16 | 6,430 | $7,430 | 585,934 | -1.1% |
| 2024-03-29 01:01 | 2024-03-27 | Hasnain Faheem | Director, Officer - President & CEO | SELL | $1.16 | 23,172 | $26,773 | 120,293 | -16.2% |
| 2024-03-20 01:50 | 2024-03-18 | Aranda Richard | Officer - Chief Medical Officer | SELL | $1.33 | 4,018 | $5,342 | 198,799 | -2.0% |
| 2024-03-20 01:50 | 2024-03-18 | Peterson Caryn | Officer - EVP, Regulatory Affairs | SELL | $1.33 | 4,018 | $5,343 | 49,833 | -7.5% |
| 2023-11-18 00:01 | 2023-11-15 | Milligan Sandra | Director | BUY | $0.79 | 32,000 | $25,213 | 32,000 | +100.0% |
| 2023-11-15 02:24 | 2023-11-13 | Giraudo Bryan | Officer - COO/CFO | BUY | $0.56 | 200,000 | $112,880 | 380,010 | +111.1% |
| 2023-06-26 23:01 | 2023-06-22 | Aranda Richard | Officer - Chief Medical Officer | SELL | $1.29 | 1,814 | $2,340 | 197,574 | -0.9% |
| 2023-04-05 23:26 | 2023-04-04 | Giraudo Bryan | Officer - COO/CFO | BUY | $1.02 | 55,000 | $56,095 | 125,990 | +77.5% |
| 2023-03-23 00:17 | 2023-03-20 | Giraudo Bryan | Officer - COO/CFO | BUY | $0.97 | 50,000 | $48,435 | 70,990 | +238.2% |
| 2023-03-23 00:19 | 2023-03-20 | Christian Waage | Officer - EVP, Tech Ops and Admin | BUY | $1.20 | 18,500 | $22,145 | 32,388 | +133.2% |
| 2023-03-23 00:14 | 2023-03-20 | Hasnain Faheem | Director, Officer - President & CEO | BUY | $1.14 | 878,572 | $1,000,430 | 4,495,897 | +24.3% |
| 2023-03-20 16:22 | 2023-03-16 | Carter Laura | Officer - Chief Scientific Officer | SELL | $1.10 | 6,029 | $6,620 | 76,263 | -7.3% |
| 2023-03-20 16:21 | 2023-03-16 | Aranda Richard | Officer - Chief Medical Officer | SELL | $1.10 | 7,563 | $8,304 | 199,388 | -3.7% |
| 2023-03-20 16:19 | 2023-03-16 | Peterson Caryn | Officer - EVP, Regulatory Affairs | SELL | $1.10 | 7,564 | $8,305 | 53,851 | -12.3% |
| 2022-10-25 23:59 | 2022-10-24 | Peterson Caryn | Officer - EVP, Regulatory Affairs | SELL | $12.07 | 4,757 | $57,431 | 61,415 | -7.2% |
| 2022-10-25 23:57 | 2022-10-24 | Carter Laura | Officer - Chief Scientific Officer | SELL | $12.07 | 4,876 | $58,868 | 82,292 | -5.6% |
| 2022-10-25 23:55 | 2022-10-24 | Aranda Richard | Officer - Chief Medical Officer | SELL | $12.07 | 4,757 | $57,431 | 205,430 | -2.3% |
| 2022-07-15 23:27 | 2022-07-15 | Carter Laura | Officer - Chief Scientific Officer | BUY | $7.21 | 6,934 | $49,994 | 87,168 | +8.6% |
| 2022-07-15 23:23 | 2022-07-15 | Giraudo Bryan | Officer - COO/CFO | BUY | $7.21 | 13,869 | $99,995 | 20,990 | +194.8% |
| 2022-07-15 23:25 | 2022-07-15 | Christian Waage | Officer - EVP, Tech Ops and Admin | BUY | $7.21 | 6,934 | $49,994 | 13,888 | +99.7% |
| 2022-07-15 23:21 | 2022-07-15 | Hasnain Faheem | Director, Officer - President & CEO | BUY | $7.21 | 138,696 | $999,998 | 3,617,325 | +4.0% |
| 2022-07-05 23:39 | 2022-07-01 | Carter Laura | Officer - Chief Scientific Officer | SELL | $8.25 | 8,808 | $72,648 | 80,234 | -9.9% |
| 2022-06-24 01:47 | 2022-06-22 | Aranda Richard | Officer - Chief Medical Officer | SELL | $6.88 | 1,778 | $12,233 | 209,897 | -0.8% |
| 2022-05-06 01:14 | 2022-05-04 | Carter Laura | Officer - Chief Scientific Officer | SELL | $7.20 | 1,262 | $9,086 | 89,042 | -1.4% |
| 2022-03-24 23:53 | 2022-03-23 | Giraudo Bryan | Officer - COO/CFO | SELL | $8.92 | 10,722 | $95,587 | 99,167 | -9.8% |
| 2022-03-24 23:57 | 2022-03-23 | Christian Waage | Officer - EVP, Tech Ops and Admin | SELL | $8.92 | 10,722 | $95,587 | 579,008 | -1.8% |
| 2022-03-24 23:55 | 2022-03-23 | Hasnain Faheem | Director, Officer - President & CEO | SELL | $8.92 | 19,035 | $169,697 | 143,465 | -11.7% |
| 2022-03-18 00:03 | 2022-03-16 | Carter Laura | Officer - Chief Scientific Officer | SELL | $8.28 | 5,002 | $41,407 | 90,304 | -5.2% |
| 2022-03-18 00:00 | 2022-03-16 | Peterson Caryn | Officer - EVP, Regulatory Affairs | SELL | $8.28 | 6,279 | $51,978 | 66,172 | -8.7% |
| 2022-03-17 23:58 | 2022-03-16 | Aranda Richard | Officer - Chief Medical Officer | SELL | $8.28 | 6,278 | $51,976 | 211,675 | -2.9% |
| 2021-10-27 00:08 | 2021-10-25 | Peterson Caryn | Officer - EVP, Regulatory Affairs | SELL | $12.25 | 2,377 | $29,118 | 72,451 | -3.2% |
| 2021-10-27 00:01 | 2021-10-25 | Carter Laura | Officer - Chief Scientific Officer | SELL | $12.25 | 2,377 | $29,118 | 95,306 | -2.4% |
| 2021-10-26 23:58 | 2021-10-25 | Aranda Richard | Officer - Chief Medical Officer | SELL | $12.25 | 2,377 | $29,118 | 217,432 | -1.1% |
| 2021-03-25 23:13 | 2021-03-23 | Salter-Cid Luisa | Officer - Chief Scientific Officer | SELL | $9.48 | 5,491 | $52,052 | 206,065 | -2.6% |
| 2021-03-25 23:11 | 2021-03-23 | Giraudo Bryan | Officer - Chief Financial Officer | SELL | $9.48 | 5,490 | $52,046 | 109,889 | -4.8% |
| 2021-03-25 23:09 | 2021-03-23 | Christian Waage | Officer - EVP & General Counsel | SELL | $9.48 | 5,490 | $52,051 | 588,199 | -0.9% |
| 2020-10-15 02:27 | 2020-10-14 | Giraudo Bryan | Officer - Chief Financial Officer | BUY | $10.01 | 3,000 | $30,036 | 7,121 | +72.8% |
| 2020-10-15 02:29 | 2020-10-14 | Christian Waage | Officer - EVP & General Counsel | BUY | $9.53 | 2,500 | $23,818 | 6,954 | +56.1% |
| 2020-10-15 02:28 | 2020-10-14 | Hasnain Faheem | Director | BUY | $10.36 | 96,520 | $999,995 | 3,478,629 | +2.9% |
| 2020-06-24 00:01 | 2020-06-23 | Giraudo Bryan | Officer - Chief Financial Officer | BUY | $12.96 | 2,000 | $25,922 | 4,121 | +94.3% |
| 2020-01-01 01:00 | 2019-12-27 | Dupont Jakob | Officer - Chief Medical Officer | OPT+S | $15.04 | 41,994 | $631,539 | 0 | 0.0% |
| 2019-09-27 17:39 | 2019-09-27 | Gujrathi Sheila | Director, Officer - President & CEO | BUY | $16.80 | 10,000 | $167,980 | 4,048,242 | +0.2% |
| 2019-09-27 17:46 | 2019-09-27 | Christian Waage | Officer - EVP & General Counsel | BUY | $16.65 | 1,000 | $16,654 | 4,454 | +29.0% |
| 2019-09-27 17:41 | 2019-09-27 | Hasnain Faheem | Director | BUY | $16.80 | 10,000 | $167,980 | 3,382,109 | +0.3% |
How to Interpret $GOSS Trades
Not every insider transaction in Gossamer Bio, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GOSS shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for GOSS
Insider activity data for Gossamer Bio, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GOSS, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.